Drugs that contain Taliglucerase Alfa
1. Elelyso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8741620 | PFIZER | Human lysosomal proteins from plant cell culture |
Feb, 2024
(2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8227230 | PFIZER | Human lysosomal proteins from plant cell culture |
Feb, 2024
(2 months ago) | |
| US8790641 | PFIZER | Production of high mannose proteins in plant culture and therapeutic uses thereof |
Oct, 2025
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 27, 2017 |
| New Chemical Entity Exclusivity(NCE) | May 01, 2017 |
NCE-1 date: 01 May, 2016
Market Authorisation Date: 01 May, 2012
Treatment: A method of catalyzing the hydrolysis of glucocerebroside to glucose and ceramide.
Dosage: POWDER;IV (INFUSION)
More Information on Dosage
ELELYSO family patents
